Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial

Christoph Wanner, Mark E. Cooper, Odd Erik Johansen, Robert Toto, Julio Rosenstock, Darren K. McGuire, Steven E. Kahn, Egon Pfarr, Sven Schnaidt, Maximilian von Eynatten, Jyothis T. George, Nicholas D. Gollop, Nikolaus Marx, John H. Alexander, Bernard Zinman, Vlado Perkovic, CARMELINA investigators

Norwich Medical School

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

7 Downloads (Pure)

3 Citations (Scopus)
1 Article

1 results

2021

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial
Wanner, C., Cooper, M. E., Johansen, O. E., Toto, R., Rosenstock, J., McGuire, D. K., Kahn, S. E., Pfarr, E., Schnaidt, S., von Eynatten, M., George, J. T., Gollop, N. D., Marx, N., Alexander, J. H., Zinman, B., Perkovic, V. & CARMELINA Invest, Sep 2021, In: Clinical Kidney Journal. 14, 9, p. 2136 1 p.
Research output: Contribution to journal › Article › peer-review

Open Access

Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial

Research output

Search results

Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial